1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Mental Health Market Trends
  5. > EpiCast Report: Alzheimer’s Disease - Epidemiology Forecast to 2023

EpiCast Report: Alzheimer’s Disease - Epidemiology Forecast to 2023

Summary

AD is an irreversible, neurodegenerative brain disease of the elderly, which leads to a progressive decline in memory and cognitive abilities, such as thinking, language, and learning capacity. Similar to AD, mild cognitive impairment (MCI) is also a condition of the elderly in which there is a slight but noticeable and measurable decline in cognitive abilities, including memory and thinking skills, but no dementia.

To forecast the total prevalent cases of AD in adults ages =60 years in the 9MM during the forecast period (2013-2023), GlobalData epidemiologists identified country-specific population-based studies that used the diagnostic criteria based on the Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised (DSM-III-R) to diagnose dementia, and the National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria to diagnose AD. Similarly, to forecast the total prevalent cases of MCI in the 9MM, GlobalData’s epidemiologists selected country-specific studies that defined MCI as a “slight but noticeable and measurable decline in cognitive abilities, including memory and thinking skills, but no dementia.” Additionally, GlobalData epidemiologists kept the forecast methodology consistent across the 9MM in order to allow for a meaningful comparison of the total prevalent cases between the markets.

GlobalData epidemiologists forecast that by 2023, there will be approximately 17.38 million total prevalent cases of AD across the 9MM covered in this analysis. GlobalData epidemiologists expect a 34.3% increase in the total prevalent cases of AD in the 9MM over the next decade. Similarly, GlobalData epidemiologists forecast that the total prevalent cases of MCI in the 9MM will increase from 82.25 million cases in 2013 to 108.41 million cases in 2013 at a decadal growth rate of 31.80%.

Scope

- The Alzheimer’s disease (AD) EpiCast Report provides an overview of the risk factors and global trends of AD in the 9MM (US, France, Germany, Italy, Spain, UK, Japan, China, and India). The series also includes a 10-year epidemiological forecast for the total prevalent cases of AD segmented by sex, age, and severity in these markets. In addition, the report includes a 10-year epidemiological forecast for the total prevalent cases of mild cognitive impairment (MCI) segmented by sex and age in these markets.
- The AD epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 9MM.

Reasons to buy

- Develop business strategies by understanding the trends shaping and driving the global AD market.
- Quantify patient populations in the global AD market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for AD therapeutics in each of the markets covered.
- Identify the percentage of AD prevalent cases by severity and identify the number of cases with MCI.

Table Of Contents

EpiCast Report: Alzheimer’s Disease - Epidemiology Forecast to 2023
1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 6
1.2 List of Figures 7
2 Introduction 8
2.1 Related Reports 9
2.2 Upcoming Related Reports 9
3 Epidemiology 10
3.1 Disease Background 10
3.2 Risk Factors and Comorbidities 11
3.2.1 A family history of Alzheimer's increases the risk of developing the disease by 7.5 times 12
3.2.2 The APOE ?4 allele triples the risk for AD 13
3.2.3 Cardiovascular risk factors in midlife significantly increase the risk of developing AD in later life 13
3.2.4 The incidence and prevalence of AD double every five years after age 65 years 14
3.2.5 Diabetes doubles the risk of AD in men, but only marginally affects the risk in women 14
3.2.6 Women are 1.5 times more likely to develop AD than men 15
3.2.7 Depression triples the risk for AD, and is the most common comorbidity 15
3.2.8 Up to 70% of AD patients also suffer from anxiety 16
3.2.9 Psychosis and agitation are common comorbidities in Alzheimer's patients 16
3.3 Global Trends 16
3.3.1 US 17
3.3.2 5EU 18
3.3.3 Japan 20
3.3.4 China 21
3.3.5 India 21
3.4 Forecast Methodology 22
3.4.1 Sources Used 27
3.4.2 Forecast Assumptions and Methods 34
3.4.3 Sources Not Used 45
3.5 Epidemiology Forecast (2013-2023) 47
3.5.1 Total Prevalent Cases of AD 47
3.5.2 Age-Specific Total Prevalent Cases of AD 49
3.5.3 Sex-Specific Total Prevalent Cases of AD 51
3.5.4 Age-Standardized Total Prevalence of AD 54
3.5.5 Total Prevalent Cases of AD, by Severity 55
3.5.6 Total Prevalent Cases of MCI 57
3.5.7 Age-Specific Total Prevalent Cases of MCI 59
3.5.8 Sex-Specific Total Prevalent Cases of MCI 61
3.5.9 Age-Standardized Total Prevalence of MCI 63
3.6 Discussion 65
3.6.1 Conclusions Regarding the Epidemiological Trends 65
3.6.2 Limitations of the Analysis 67
3.6.3 Strengths of the Analysis 68
4 Appendix 69
4.1 Bibliography 69
4.2 About the Authors 77
4.2.1 Epidemiologist 77
4.2.2 Reviewers 77
4.2.3 Global Director of Therapy Analysis and Epidemiology 78
4.2.4 Global Head of Healthcare 79
4.3 About GlobalData 80
4.4 About EpiCast 80
4.5 Disclaimer 81

1.1 List of Tables
Table 1: Risk Factors and Comorbidities for AD 12
Table 2: DSM-III-R Criteria for the Diagnosis of Dementia 22
Table 3: NINCDS-ADRDA Criteria for the Diagnosis of AD 23
Table 4: 9MM, Epidemiological Sources for AD Total Prevalence Data 24
Table 5: 9MM, Epidemiological Sources for AD Total Prevalence Data, Based on Severity 25
Table 6: 9MM, Epidemiological Sources for MCI Total Prevalence Data 26
Table 7: 9MM, Sources Excluded from the Forecast for the Total Prevalent Cases of AD 46
Table 8: 9MM, Sources Excluded from the Forecast for the Total Prevalent Cases of MCI 46
Table 9: 9MM, Total Prevalent Cases of AD, Ages ?60 Years, Men and Women, N, 2013-2023 48
Table 10: 9MM, Total Prevalent Cases of AD, by Age, Men and Women, N (Row %), 2013 50
Table 11: 9MM, Total Prevalent Cases of AD, by Sex, Age ? 60 Years, N (Row %), 2013 52
Table 12: 9MM, Total Prevalent Cases of AD, by Severity, Men and Women, N (Row %), 2013 56
Table 13: 9MM, Total Prevalent Cases of MCI, Ages ?60 Years, Men and Women, N, 2013-2023 58
Table 14: 9MM, Total Prevalent Cases of MCI, by Age, Men and Women, N (Row %), 2013 60
Table 15: 9MM, Total Prevalent Cases of MCI, by Sex, Age ?60 Years, N (Row %), 2013 62

1.2 List of Figures
Figure 1: 9MM, Total Prevalent Cases of AD, Ages ?60 Years, Men and Women, N, 2013-2023 48
Figure 2: 9MM, Total Prevalent Cases of AD, by Age, Men and Women, N, 2013 51
Figure 3: 9MM, Total Prevalent Cases of AD, by Sex, Age ?60 Years, N, 2013 53
Figure 4: 9MM, Age-Standardized Total Prevalence of AD, Age ?60 Years, Men and Women, %, 2013 55
Figure 5: 9MM, Total Prevalent Cases of AD, by Severity, Men and Women, N, 2013 57
Figure 6: 9MM, Total Prevalent Cases of MCI, Ages ?60 Years, Men and Women, N, 2013-2023 59
Figure 7: 9MM, Total Prevalent Cases of MCI, by Age, Men and Women, N, 2013 61
Figure 8: 9MM, Total Prevalent Cases of MCI, by Sex, Age ?60 Years, N, 2013 63
Figure 9: 9MM, Age-Standardized Total Prevalence of MCI, Age ?60 Years, Men and Women, %, 2013 65

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Alzheimer’s disease (AD) - Market Insights, Epidemiology and Market Forecast-2023

Alzheimer’s disease (AD) - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

DelveInsight’s Alzheimer’s disease (AD) - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global market trends of the Alzheimer’s disease ...

Amyotrophic lateral sclerosis (ALS)- Market Insights, Epidemiology and Market Forecast-2023

Amyotrophic lateral sclerosis (ALS)- Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Amyotrophic lateral sclerosis (ALS) - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of ...

Global Multi Infarct Dementia Market Insights, Opportunity Analysis, Market Shares and Forecast, 2016 - 2022

Global Multi Infarct Dementia Market Insights, Opportunity Analysis, Market Shares and Forecast, 2016 - 2022

  • $ 3900
  • Industry report
  • November 2016
  • by Occams

"Global Multi Infarct Dementia Market Research Report 2016" by OBRC, is an extensive study on present state of the Multi Infarct Dementia Market. The global multi-infarct dementia is estimated to reach ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.